Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-11-06
2007-11-06
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000
Reexamination Certificate
active
10625059
ABSTRACT:
The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
REFERENCES:
patent: 3946033 (1976-03-01), Iwata et al.
patent: 5041542 (1991-08-01), Robins et al.
patent: 5324731 (1994-06-01), Kaddurah-Daouk et al.
patent: 5780492 (1998-07-01), Dinsmore et al.
patent: 5880284 (1999-03-01), Himmelsbach et al.
patent: 6043228 (2000-03-01), McMurry et al.
patent: 6184382 (2001-02-01), Salazar et al.
patent: 2006/0166926 (2006-07-01), Wilde et al.
patent: 0 612 741 (1994-02-01), None
patent: WO96/11930 (1996-04-01), None
patent: WO97/24327 (1997-07-01), None
patent: WO97/45400 (1997-12-01), None
patent: WO 00/24707 (2000-05-01), None
The Oxford Textbook of Oncology, 1995, published by Oxford University Press, pp. 447-453.
The Merck Manual of Diagnosis and Therapy, seventeenth edition, 1999, Published by Merck Research Laboratories, pp. 397-398, 948-949, 1916, and 1979-1981.
Sanghvi et al., “Antitumor and Antiviral Activity of Synthetic alpha- and beta- Ribonucleotides of Certain Substituted Pyrimido[5,4-d]pyrimidines: A new Synthetic Strategy for Exocyclic Aminonucleosides” J. Med. Chem. (1989) vol. 32, pp. 629-637.
Elliot, R.D., et al.,J. Med. Chem. 19:1186-1191 (1976).
Greenberg, M.M., et al.,Biochemistry 40:15856-15861 (2001).
Palmer, C.F., et al.,Tet. Lett.31:279-282 (1990).
Barton-Davis et al., 1999, “Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice,” J. Clin. Invest. 104(4):375-381.
Baxter et al., 1991, “Synthesis and Biological Activity of Carbocyclic Clitocine,” Nucleosides & Nucleotides 10(1-3):393-396.
Bedwell et al., 1997, “Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line,” Nat Med. 3(11):1280-4.
Burgdorf et al., 2002, “Synthesis, stability, and conformation of the formamidopyrimidine G DNA Lesion,” Chem. Eur. J. 8(1):293-301.
Espie et al., 1990, “Synthesis of a Nitro Group Containing Ribonucleoside Related to Guanosine,” Tetrahedron Letters 31(10):1423-1426.
Franchetti et al., 1995, “Acyclic Nucleotides Related to Clitocin: Synthesis and Anti-HIV Activity,” Nucleosides & Nucleotides 14(3-5):607-610.
Franchetti et al., 1991, “Synthesis Of 3-Deazaclitocine [2-Amino-3-Nitro-4-(β-D-Ribofuranosylamino)Pyridine] As Cytotoxic Agent,” Nucelosides & Nucleotides 10(1-3):543-545.
Ghose et al., 1990, “Structural Studies Of The Novel Antitumor Agents 4-Amino-8-(β-D-Ribofuranosylamino)Pyrimido[5,4-D]Pyrimidines And Their A-Anomers Using X-Ray,1H NMR, And Theoretical Methods,”J. Am. Chem. Soc. 112:3622-3628.
Ghose et al., 1989, “Structural Mimicry Of Adenosine By The Antitumor Agents 4-Methoxy- And 4-Amino-8-(B-D-Ribofuranosylamino)Pyrimido-[5,4-d]Pyrmidine As Viewed By A Molecular Modeling Method,” PNAS 86:8242-8246.
Grem et al., 1994, “Cytotoxicity and metabolism of 4-Methoxy-8-(β-D-Ribofuranosylamino)Pyrimido[5,4-d]Pyrimidine in HCT 116 Colon Cancer Cells,” Biochem. Pharmacol. 48(11):2117-2126.
Hollstein et al., 1994, “Database of p53 gene somatic mutations in human tumors and cell lines,” Nucleic Acids Res. 22(17):3551-3555.
Howard et al., 1996, “Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations,” Nat Med. 2(4):467-469.
Kamikawa et al., 1988, J. Chem. Soc. Chem. Comm. 195.
Kubo et al., 1986, “Clitocine, a New Insecticidal Nucleoside from the MushroomClitocybe inversa,” Tetrahedron Letters 27(36):4277-4280.
Lee, 2001, “Clitocin Analogs to Inhibit Adenosine Kinase,” Bioorg. Med. Chem. Lett., 11:2419.
Lee et al., 2001, “Synthesis and Biological Evaluation of Clitocine Analogues as Adenosine Kinase Inhibitors,” Bioorg. & Med. Chem. Letters 11:2419-2422.
Mabry et al., 1994, “Synthesis Of 4-Amino-8-(2,2-Difluoro-2-Deoxy-β-D-Ribo Furanosyl Amino)Pyrimido[5,4-D]Pyrimidine (DFARPP). Stability And Cellular Cytotoxicity,” Nucleosides and Nucleotides 13(5):1125-1133.
Moss et al., 1988, “Synthesis, Intramolecular Hydorgen Bonding, And Biochemical Studies Of Clitocine, A Naturally Occurring Exocyclic Amino Nucleoside,” J. Med. Chem. 31:786-790.
Nogueras et al., 1994, “Selective Synthesis of 6-Ribo- (and Xylo) Pyrano and Furano Aminopyrimidines. Anticancer and Anti-AIDS Activities,” Nucleosides & Nucleotides 13(1-3):447-457.
Palmer et al., 1990, “Synthesis of Carbocyclic Clitocine,” Tetrahedron Letters 31(2):279-282.
Sleat et al., 2001, “Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis,” Eur. J. Paediatr. Neurol. 5 Suppl A:57-62.
Vincze et al., 1972, “Reaction of Diethyl Pyrocarbonate with Nucleic Acid Components. Bases and Nucleosides Derived from Guanine, Cytosine, and Uracil,” J. Am. Chem. Soc. 95(8):2677-2682.
Zambetti et al., 1993, “A comparison of the biological activities of wild-type and mutant p53,” FASEB J. 7(10):855-865.
Koshland, D., 1993, “Molecule of the year,” Science 262(5142):1953.
Almstead Neil G.
Friesen Westley J.
Kennedy Paul D.
Takasugi James J.
Welch Ellen M.
Jones Day
Olson Eric S
PTC Therapeutics, Inc.
LandOfFree
Nucleoside compounds and their use for treating cancer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside compounds and their use for treating cancer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside compounds and their use for treating cancer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808920